focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

Mon, 18th Dec 2023 07:55

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Last week saw a rally in stock markets across the globe, thanks to a dovish pivot from the US Federal Reserve, though the FTSE 100 underperformed somewhat. This week, investors will be keeping a close eye on Friday's US personal consumption expenditures price index data - the Fed's preferred metric of inflation.

Another key focal point for the week will be the Bank of Japan's monetary policy decision to be announced on Tuesday.

"There is nothing more than a slim probability for the BoJ to exit negative rates this week, but investors are eager to hear further details about how and when the BoJ will leave the negative rate territory," said Swissquote Bank senior analyst Ipek Ozkardeskaya.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 10.4 points, 0.1%, at 7,561.96

----------

Hang Seng: down 1.1% at 16,612.95

Nikkei 225: closed up 0.6% at 32,758.98

S&P/ASX 200: closed down 0.2% at 7,426.40

----------

DJIA: closed up 0.2%, at 37,305.16

S&P 500: closed little changed at 4,719.19

Nasdaq Composite: closed up 0.4% at 14,813.92

----------

EUR: up at USD1.0919 (USD1.0912)

GBP: down at USD1.2689 (USD1.2693)

USD: up at JPY142.26 (JPY141.75)

GOLD: down at USD2,023.33 per ounce (USD2,034.62)

OIL (Brent): up at USD77.31 a barrel (USD76.34)

(changes since previous London equities close)

----------

ECONOMICS

----------

Monday's key economic events still to come:

10:00 CET Germany Ifo business climate index

09:30 GMT UK card spending statistics

10:00 EST US NAHB housing market index

----------

BROKER RATING CHANGES

----------

Morgan Stanley cuts Fresnillo to 'underweight' (equal-weight) - price target to 540 (620) pence

----------

UBS cuts Barratt Developments to 'neutral' (buy) - price target 610 (495) pence

----------

UBS raises Taylor Wimpey to 'buy' (neutral) - price target 160 (126) pence

----------

COMPANIES - FTSE 100

----------

Spirax-Sarco Engineering named Louisa Burdett as its new chief financial officer, with a starting date of July next year. Burdett is currently CFO at Croda International, and has led finance functions at "several large companies" including Meggitt and Victrex. Spirax-Sarco said CFO Nimesh Patel, who was previously announced to be its new CEO, will take the helm of the firm on January 16. Group finance director, Phil Scott, will be interim CFO from that date until Burdett joins the company. Croda International noted Burdett's departure, and said it has begun the search for her successor. Additionally, Croda said adjusted pretax profit was likely to come at the lower end of its guidance of GBP300 million to GBP320 million range, mostly due to recent currency movements, especially in Argentina.

----------

GSK announced positive headline results from the second part of its phase III trial of Jemperli plus standard-of-care chemotherapy, followed by dostarlimab plus Zejula as maintenance therapy, in adult patients with primary advanced or recurrent endometrial cancer. "The trial, which evaluated this combination against placebo plus chemotherapy followed by placebo, met its primary endpoint of progression-free survival, with a statistically significant and clinically meaningful benefit observed in both the overall patient population and in a subpopulation of patients with mismatch repair proficient/microsatellite stable tumours," GSK explained.

----------

The Financial Times reported that GSK is looking for some new deals in China. This comes after GSK rebuilt a "very strong" relationship with the government and local companies since a corruption scandal a decade ago, the newspaper said. Chief Commercial Officer Luke Miels told the FT that GSK is working on further deals with Chinese companies after it signed a licensing agreement in October worth up to USD1.5 billion for a cancer drug developed by Hansoh Pharmaceutical Group.

----------

Frasers Group is in talks to buy Matchesfashion, a luxury clothing retailer, from its private equity owner since 2017, Apax Partners, Sky News reported on Saturday. Citing "City sources", Sky said Frasers is among a small group of bidders that submitted offers early last week. Frasers would likely pay in excess of GBP50 million for Matchesfashion, whose business has struggled, according to Sky, citing an "insider". Sky said fellow London-listed retailer Next also is said to have expressed an interest in buying Matchesfashion.

----------

COMPANIES - FTSE 250

----------

Games Workshop has entered an agreement with Amazon's Content Services subsidiary for the prospective development of its Warhammer 40,000 universe into films and television series, alongside the associated merchandising rights. The deal grants exclusive rights to Amazon for film and TV series set within the universe, as well as an option for exclusive rights in the Warhammer Fantasy universe down the line. "Games Workshop and Amazon will work together for a period of 12 months to agree creative guidelines for the films and television series to be developed by Amazon. The agreement will only proceed once the creative guidelines are mutually agreed between Games Workshop and Amazon," the UK company said. It added that it will make no change to its forecast for its financial year ending in June. Games Workshop had announce an agreement in principle with Amazon in December last year.

----------

IP Group has launched a share buy back for up to GBP20 million. The intellectual property investor said the programme came in light of the discount of its share price to its net asset value per share, and it determined now to be "an appropriate time".

----------

OTHER COMPANIES

----------

Hollywood Bowl held its annual dividend unchanged and announced plans for a share buyback worth up to GBP10 million. The operator of ten-pin bowling centres reported pretax profit of GBP45.1 million for the financial year that ended September 30, down from GBP46.7 million in financial 2022, which benefited from a reduced rate of value-added tax on bowling.

----------

Canadian Overseas Petroleum said its non-binding Cole Creek joint venture letter of intent has been terminated, and it plans "no further discussions at this stage". Back in July, COPL had announced the potential joint venture with "an established energy company" to develop and exploit oil reserves at the Cole Creek in Converse and Natrona counties, Wyoming. "The company will provide a further update before year end regarding its strategy relating to the development of its Cole Creek and Barron Flats Shannon Units," COPL said on Monday.

----------

By Elizabeth Winter, Alliance News deputy news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.